

IN THE CLAIMS

Please amend the claims as follows:

Claims 1-43 (Cancelled)

44. (New) A medical product comprising a dry powder dose comprising at least one of tiotropium and physiologically acceptable salts thereof directly loaded into a container adapted for administration by a dry powder inhaler, wherein

a dry, moisture-tight, barrier seal constitutes the container;

the moisture-tight barrier seal of the container prevents ingress of moisture into the powder dose whereby an original fine particle fraction of the powder dose is preserved for at least seven days, and

a delivered fine particle dose of said at least one of tiotropium and physiologically acceptable salts thereof from said medical product is generally independent of variations in ambient humidity conditions.

45. (New) The medical product according to claim 44, wherein

the original fine particle fraction of the powder dose is preserved for at least fourteen days.

46. (New) The medical product according to claim 44, wherein

the container itself does not emit water.

47. (New) The medical product according to claim 44, wherein

the delivered fine particle dose of at least one of tiotropium and physiologically acceptable salts thereof constitutes at least 56 % of a delivered dose.

48. (New) The medical product according to claim 44, wherein
the delivered fine particle dose of at least one of tiotropium and physiologically
acceptable salts thereof constitutes at least 47 % of a metered dose.

49. (New) The medical product according to claim 44, wherein
the dry powder dose is adapted for inhalation from a dry powder inhaler
providing a prolonged dose delivery.

50. (New) The medical product according to claim 44, wherein
the at least one of tiotropium and physiologically acceptable salts thereof
consists of one or more physiologically acceptable salts of tiotropium.

51. (New) The medical product according to claim 44, wherein
said dose further comprises lactose.

52. (New) The medical product according to claim 44, wherein the dry, moisture-tight
barrier seal is formed on flat aluminum foils, optionally laminated with polymers.

53. (New) The medical product according to claim 44, wherein
a cavity molded from a polymer material selected to give the container
moisture-tight barrier seal properties constitutes the container.

54. (New) The medical product according to claim 44, wherein

a cavity molded from a polymer material together with a moisture-tight barrier seal constitute the container providing it with moisture-tight barrier seal properties.

55. (New) The medical product according to claim 44, wherein
the container is a part of a dry powder inhaler.

56. (New) The medical product according to claim 44, wherein
the container is a separate part adapted for insertion into a dry powder inhaler

57. (New) The medical product according to claim 44, wherein
the container is a separate part comprising a primary part adapted for insertion into a dry powder inhaler and a secondary part enclosing the primary part in a moisture-tight package.

58. (New) The medical product according to claim 44, wherein
the medical product is adapted for use in the treatment of respiratory disorders.

59. (New) A medical product comprising at least one of tiotropium and physiologically acceptable salts thereof and at least one additional active pharmaceutical ingredient and optionally including at least one excipient in a dry powder medical combination dose directly loaded into a container, wherein

a dry, moisture-tight barrier seal constitutes the container;

the moisture-tight barrier seal of the container prevents ingress of moisture whereby an original fine particle fraction of the combination dose is preserved for at least seven days;

the combination dose is adapted for administration by a dry powder inhaler,
a delivered fine particle dose of the combination dose is generally independent
of variations in ambient humidity conditions, and

the at least one additional active pharmaceutical ingredient is selected from
inhalable steroids, nicotinamide derivatives, beta-agonists, beta-mimetics, anti-histamines,
adenosine A2A receptors, PDE4 inhibitors, and dopamine D2 receptor agonists.

60. (New) The medical product according to claims 59, wherein
the original fine particle fraction of the combination dose is preserved for at
least fourteen days.

61. (New) The medical product according to claim 59, wherein
the container itself does not emit water.

62. (New) The medical product according to claim 59, wherein
the delivered fine particle dose of the combination dose constitutes at least 56 % of a
delivered dose.

63. (New) The medical product according to claim 59, wherein
the delivered fine particle dose of the combination dose constitutes at least 47 % of a
metered dose.

64. (New) The medical product according to claim 59, wherein
the product is adapted for administration by inhalation from a dry powder inhaler providing a
prolonged dose delivery.

65. (New) The medical product according to claim 59, wherein
the at least one of tiotropium and physiologically acceptable salts thereof
consists of one or more physiologically acceptable salts of tiotropium.
66. (New) The medical product according to claim 59, comprising
excipient lactose.
67. (New) The medical product according to claim 59, wherein
the dry, moisture-tight barrier seal is formed of flat aluminum foils, optionally
laminated with polymers.
68. (New) The medical product according to claim 59, wherein
a cavity molded from a polymer material selected to give the container
moisture-tight barrier seal properties constitutes the container.
69. (New) The medical product according to claim 59, wherein
a cavity molded from a polymer material together with a moisture-tight barrier
seal constitute the container providing it with moisture-tight barrier seal properties.
70. (New) The medical product according to claim 59, wherein
the container is a part of a dry powder inhaler.
71. (New) The medical product according to claim 59, wherein
the container is a separate part adapted for insertion into a dry powder inhaler

72. (New) The medical product according to claim 59, wherein
the container is a separate part comprising a primary part adapted for insertion
into a dry powder inhaler and a secondary part enclosing the primary part in a moisture-tight
package.

73. (New) The medical product according to claim 59, wherein
the medical product is adapted for use in the treatment of respiratory disorders.